Vioxx was marketed by Mrck & Co. to treat osteoarthritis, acute pain conditions and dysmenorrhoea. On September 30, 2004 Merck voluntarily withdrew Vioxx from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.